Evolution of hypertensive disease: a revolution in guidelines

Lancet

Volumn 368, Issue 9529, 2006, Pages 6-8

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; METABOLIC DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; UNITED KINGDOM;

EID: 33745334999     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68943-5     Document Type: Note

References (13)

1. Kearney P., Whelton M., Reynolds K., Muntner P., Whelton P., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
2. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 45 (2005) 813-827
3. NICE/BHS. Clinical guideline 34: hypertension: management of hypertension in adults in primary care: partial update. http://www.nice.org.uk/CG034guidance (accessed June 28, 2006)
4. Dahlöf B., Devereux R., Kjeldsen S., and for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
5. Dahlöf B., Sever P., Poulter N., and for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
6. Lindholm L., Carlberg B., and Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
7. Mason J., Dickinson H., Nicolson D., Campbell F., Ford G., and Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 3 (2005) 1777-1781
8. Williams B. Insulin resistance: the shape of things to come. Lancet 344 (1994) 521-524
9. Vasan R., Larson M., Leip E., Kannel W., and Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358 (2001) 1682-1686
10. de Simone G., Devereux R., Chinali M., and for the Strong Heart Study Investigators. Risk factors for arterial hypertension in adults with initial optimal blood pressure. Hypertens 47 (2006) 162-167
11. Dickerson J., Hingorani A., Ashby M., Palmer C., and Brown M. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353 (1999) 2008-2013
12. Deary A., Schumann A., Murfet H., Haydock S., Foo R., and Brown M. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 20 (2002) 771-777
13. Julius S., Nesbitt S., Egan B., and Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697